IP Library Granted Patent US 11,896,572
Granted Patent B2
US 11,896,572 · App. 18/231,581 · Granted Feb 13, 2024

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Inventors: Jordan Dubow (Lyons, FR); Hervé Guillard (Villeurbanne, FR); Claire Mégret (Lyons, FR); Jean-François Dubuisson (Lyons, FR)
Assignee: Flamel Ireland Limited
A61K31/22A61K9/14A61K9/1676A61K9/5015A61K9/5026A61K9/5042A61K9/5078A61K9/5084A61K31/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,896,572
App. No.
18/231,581
Granted
Feb 13, 2024
Kind
B2
Abstract

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Claims (14)

1. A pharmaceutical composition comprising:

immediate release particles, each of which comprises:

a core consisting of microcrystalline cellulose; and

a sodium oxybate loaded layer covering the core and containing a binder comprising povidone, wherein the immediate release particles have a volume mean diameter of 150 to 400 microns;

delayed release particles having a pH trigger, each delayed release particle comprising:

a core consisting of microcrystalline cellulose;

a sodium oxybate loaded layer covering the core of each delayed release particle and containing a binder comprising povidone; and

a coating covering the sodium oxybate loaded layer of each delayed release particle, wherein the coating consists essentially of hydrogenated vegetable oil, methacrylic acid copolymer type C and methacrylic acid copolymer type B, wherein a weight ratio of the hydrogenated vegetable oil to the copolymers types B and C is from 0.4 to 4, and wherein the coating is from 10 to 50% of the weight of the delayed release particles, and wherein the delayed release particles have a volume mean diameter of 200 to 800 microns;

a suspending or viscosifying agent comprising 2% to 5% by weight of the composition, the suspending or viscosifying agent being a mixture of xanthan gum, carrageenan and hydroxyethylcellulose; and

an acidifying agent comprising 1.2% to 5% by weight of the composition, the acidifying agent being malic acid,

wherein the composition comprises from 3.0 to 12.0 g of sodium oxybate,

wherein a ratio of sodium oxybate in the immediate release particles and the delayed release particles is from 40/60 to 60/40,

wherein the composition is in the form of a powder that is intended to be suspended in water prior to oral administration, and

wherein the suspending or viscosifying agent and the acidifying agent are separate from the immediate release particles and the delayed release particles.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2023
From: DUBOW, JORDAN; GUILLARD, HERVÉ; MÉGRET, CLAIRE; DUBUISSON, JEAN-FRANÇOIS
To: FLAMEL IRELAND LIMITED,
Reel/Frame 065538/0066 →
Continuity (10)
Continuation 18075980 · Dec 6, 2022
Continuation 17497393 · Oct 8, 2021
Continuation In Part 17178117 · Feb 17, 2021
Continuation In Part 16527633 · Jul 31, 2019
Continuation 16281235 · Feb 21, 2019
Continuation 15655924 · Jul 21, 2017
Provisional Application 62474330 · Mar 21, 2017
Provisional Application 62399413 · Sep 25, 2016
Provisional Application 62365812 · Jul 22, 2016
Related Publication 20230381131A1 · Nov 30, 2023
Cited By (13)
US 12,186,296 US 12,186,298 US 12,226,377 US 12,226,388 US 12,226,389 US 12,239,625 US 12,257,223 US 12,263,150 US 12,263,151 US 12,303,478 US 12,478,604 US 12,533,314 US 12,551,457